If Novak Djokovic gets nicknamed “Novax“Since his Australian misadventure, which resulted in him not being able to participate in the Australian Open for lack of a vaccine against Covid-19, the tennis player is not in denial about Sars-CoV-2.
Proof, it bought 80% of the shares of a Danish biotechnology company, QuantBioRes, which is attached to find a new treatment for Covid-19. This is revealed to AFP by the director general of biotech, Ivan Loncarevic, who indicates that the financial operation dates back to June 2020.
More precisely, the statutes of the biotech show that the tennis player and his wife together own 80% of QuantBioRes, a company which employs around twenty people, including 11 researchers, in Denmark, Slovenia, Australia and the United Kingdom.
On its website, the biotech states that it strives to help humanity “by developing a treatment and cure for retroviruses and resistant bacteria”, starting with Sars-CoV-2. The company is thus developing a peptide in order toprevent the new coronavirus from infecting our cells, and plans to launch clinical trials in Britain this summer, its chief executive said.
This astonishing announcement comes after the Serbian player was purely and simply expelled from Australia for lack of being vaccinated against Covid-19. The player was banned from entering Australian territory for three years, a heavy penalty for the world number 1, thus deprived of participating in the Australian Open tournament. Note that he could suffer the same sentence in France for Roland Garros next June, because France has also decided not to accept unvaccinated players.